Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Vikram Solar IPO Review, Analysis, Good or Bad

By Jagat Joshi
August 18, 2025

The opening date of the Vikram Solar IPO is August 19, 2025, while the closing date is August 21, 2025. The Vikram Solar IPO price band is set between ₹315 to ₹332 per share. At the same time, the face value of the IPO is ₹10 each. The company filed a DRHP to raise around ₹2,079.37 crores through an IPO.

As an investor, deciding whether the IPO is Good or Bad to invest in can often be challenging. If you are confused and worried about whether to apply or not to the Vikram Solar IPO. Then worry not, here we are describing 10 important key points & an in-depth, detailed Vikram Solar IPO review which will help you to make the decision.

Strengths and Weaknesses of Vikram Solar IPO

Strengths:

As of March 31, 2025, Vikram Solar is one of the largest Indian solar PV module manufacturers with 4.50 GW operational capacity and actual production of 1,286.10 MW.

The strong focus on research and development (R&D), strict quality control (QC) systems, and skilled talent in making solar PV modules is what attracts and retains customers.

Vikram Solar holds a strong market presence across India, operating in 19 states and 2 union territories.

The company has established a strong market reputation and a good customer base, as they understand their customer well to offer high-quality products.

Weaknesses:

In FY2025, FY2024, and FY2023, the company generated most of its revenue from solar PV modules, meaning any drop in the demand for those products can badly impact the business, cash flow, and profit.

77.50% of the company’s revenue comes from its top 5 customers, while 88.72% came from its top 10 customers as of FY25. The company mostly depends on its top customers for its revenue, any negative change with them could harm the company’s financial performance.

In case any change happens in the prices of wafers, solar PV cells, or other raw materials, or their material cost rises can badly impact the business, finances, and overall performance.

If the government reduces, removes, or stops subsidies and incentives for solar energy, then the demand for their solar modules can drop, which can hurt the business, cash flow, and overall condition.

Vikram Solar IPO Details

IPO Size	₹2,079.37 crores
Offer-for-sale	up to 17,450,882 equity shares
Fresh issue	₹1,500 crores
Price band	₹315 to ₹332
Subscription	Opens on August 19, 2025, and the closing date is on August 21, 2025
Purpose of IPO	Fresh Issue and Offer-for-Sale

Vikram Solar IPO Open and closing date?

Vikram Solar IPO will open for subscription on August 19, 2025, and close for subscription on August 21, 2025.

What is the size of the Vikram Solar IPO?

The company planned to raise funds of around ₹2,079.37 crores via IPO. This IPO comprises both a fresh issue of ₹1,500 crores and an Offer-for-sale up to 17,450,882 equity shares with a face value of ₹10 each.

What are the subscription details of the Vikram Solar IPO?

The Vikram Solar IPO price range is set at ₹315 to ₹332 per share. In this IPO, a total of 45 shares were available in 1 lot size for the minimum Retail category, and for the maximum retail category, 585 shares in 13 lot sizes were available, and for the S-HNI Minimum category, 630 shares were available in 14 lot sizes. While for the B-HNI Minimum category, 3,015 shares were available in 67 lot sizes.

To invest in this IPO, each investor category has specific investment amounts:

Retail Investors: Minimum investment of ₹14,940 and maximum investment of ₹1,94,220.
Small HNI (S-HNI): Minimum investment of ₹2,09,160.
Big HSI (S-HNI): A minimum investment of ₹10,00,980 is required.

What is the Vikram Solar IPO listing Date?

Vikram Solar is a Mainboard IPO shares will be listed on August 26, 2025, on the BSE (Bombay Stock Exchange) & NSE (National Stock Exchange).

What are the objectives of the Vikram Solar IPO Issue?

The objective behind raising funds via IPO is to utilize the funds in the investment of VSL Green Power Pvt. Ltd. to set up a 3,000 MW solar cell and 3,000 MW solar module plant in Tamil Nadu (Phase I). Some funds will be used to expand solar module capacity from 3,000 MW to 6,000 MW at the same site (Phase II). Lastly, the remaining funds will be used for the company’s corporate purposes.

About Vikram Solar

Incorporated in 2005, Vikram Solar Limited is one of the growing companies that manufactures solar photovoltaic (“ PV”) modules. Vikram Solar’s main business includes Solar PV Module Manufacturing, EPC Services, and O&M Services. The company makes high-efficiency solar panels that include PERC modules – p-type monocrystalline silicon panels, TOPCon modules – n-type monocrystalline silicon panels, and HJT modules – n-type monocrystalline silicon panels with heterojunction technology. Its manufacturing facility is located at Falta SEZ, Kolkata, West Bengal, and Oragadam, Chennai, Tamil Nadu. Its revenue for 2024 is 25,109.90 million. In order to expand market demand, it has mainly focused on a production capacity of 10.50 GW by FY26 and 15.50 GW by FY27, including building a 3 GW solar cell manufacturing plant in Tamil Nadu.

Vikram Solar IPO Financials

The company reported revenue of ₹3,459.53 crores in 2025 against ₹2,523.96 crores in 2024. The company reported a profit of ₹139.83 crores in 2025 against a Profit of ₹79.72 crores in 2024.

Vikram Solar IPO Promoters

The promoters of the company are Gyanesh Chaudhary, Gyanesh Chaudhary Family Trust, and Vikram Capital Management Private Limited.

Who are the Vikram Solar IPO lead managers and registrar?

JM Financial Limited, Nuvama Wealth Management Limited, UBS Securities India Private Limited, Equirus Capital Private Limited, PhillipCapital (India) Private Limited are the lead managers of Vikram Solar, while MUFG Intime India Private Limited is the registrar of the company.

Should you apply or not for the Vikram Solar IPO?

Are you torn between whether or not you should apply or not for the Vikram Solar IPO? Well, it is necessary to weigh its strengths/risks, your investment goals, and risk appetite before investing your money in it. Vikram Solar is one of the well-established players in the solar energy sector, with a strong domestic and international presence. With 4.50 GW of installed manufacturing capacity for solar PV modules, Vikram Solar is one of the largest companies in the play module manufacturing in India.

The company is involved in offering a wide range of high-efficiency solar PV modules and expertise in EPC and O&M services. What makes them trusted and established is their strong engineering skills to design highly automated production lines with carefully selected equipment, which helped them to improve their solar module efficiency from 17.52% in 2016 to 23.66% in 2025. If we talk about its financials, over the years, the company has shown a strong revenue growth from promoting its renewable energy. Also, in the future, the company is planning to upgrade all its solar PV module manufacturing lines to be compatible with N-Type module production. So, my final verdict is that the company is showing pretty good growth potential, and investors can evaluate the long-term growth potential from it. However, just like any other IPO, we recommend that investors first check market conditions, financials, the company’s background, and risks before making a final decision, and investing at their own risk.

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.